You are here

  • Home
  • Archive
  • Volume 61, Issue 9
  • Positive immunostaining for thyroid transcription factor-1 in colorectal adenocarcinoma using the 8G7G3/1 monoclonal antibody

Article Text

Article menu
Download PDFPDF
Letters
PostScript
Positive immunostaining for thyroid transcription factor-1 in colorectal adenocarcinoma using the 8G7G3/1 monoclonal antibody
  1. N A C S Wong1,
  2. H Kamel2,
  3. E A Sheffield3,
  4. M Sohail1
  1. 1Department of Histopathology, Bristol Royal Infirmary, Bristol, UK
  2. 2Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, UK
  3. 3Department of Cellular Pathology, Frenchay Hospital, Bristol, UK
  1. Dr Newton A C S Wong, Department of Histopathology, Bristol Royal Infirmary, Marlborough Street, Bristol BS2 8HW, UK; nacs.wong{at}bristol.ac.uk

https://doi.org/10.1136/jcp.2008.058552

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In their recent article in this journal, Penman and colleagues investigated the possibility of thyroid transcription factor-1 (TTF-1) immunostaining among colorectal adenocarcinoma (CRC) using two monoclonal antibodies.1 They found the SPT24 clone, but not the 8G7G3/1 clone, to show nuclear staining among a proportion of CRCs. All previous peer-reviewed publications on the latter TTF-1 antibody have similarly reported a complete absence of staining among primary and metastatic CRC.2–5 We now present two cases of CRC that stained positively with the 8G7G3/1 monoclonal antibody, as verified by three independent laboratories.

    Case 1 was a Caucasian man in his 60s who presented with a lower rectal tumour, biopsies of which showed CRC and background adenoma. He underwent neoadjuvant treatment, because of threatened mesorectal margins, …

    View Full Text

    Footnotes

    • Competing interests: None declared.